Coronavirus (COVID-19)
Learn more
Sponsor: Gynecologic Oncology Group/Tesaro
Number: GOG 3012
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Niraparib works by inhibiting PARP, a protein that helps cancer cells repair DNA that has been damaged by cancer treatments, especially in cancers with mutated BRCA. When cancer cells repair damaged DNA, they can continue growing and multiplying, so depriving them of this power with a PARP inhibitor may be an effective approach to treatment.
Patients in this study will be randomly assigned to receive niraparib or a placebo. Niraparib is taken orally (by mouth).
Who’s eligible:
Available at: The Hospital of Central Connecticut and Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.